Targeting evolutionarily acquired insertion sequences in Candida species, for development of antifungal drugs
针对念珠菌物种中进化获得的插入序列,用于开发抗真菌药物
基本信息
- 批准号:10592776
- 负责人:
- 金额:$ 20.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-11-18 至 2024-10-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAffinity ChromatographyAmino Acid SequenceAmino AcidsAntifungal AgentsAntifungal TherapyBiodistributionBiologicalBiological AssayBiological AvailabilityCandidaCandida albicansCandida aurisCandidiasisCarbonCell WallCellsClinicalCo-ImmunoprecipitationsCodon NucleotidesDNA Insertion ElementsDatabasesDevelopmentDisseminated candidiasisDockingDoseDrug ControlsDrug KineticsDrug TargetingEncapsulatedEpitopesEudragitEukaryotaFDA approvedFilamentFormulationFrequenciesGelGene FamilyGene ProteinsGeneric DrugsGenesGenetic ScreeningGrowthHumanHydrophobicityImmune EvasionIn VitroIndividualInvadedLeucineLigandsMass Spectrum AnalysisMedical DeviceMembraneMicrobial BiofilmsMitochondriaModelingMucous MembraneMulti-Drug ResistanceMusMutagenesisMycosesNMR SpectroscopyOpen Reading FramesOralOral AdministrationOral candidiasisOral mucous membrane structureOrganismPathogenicityPenetrationPhagocytosisPharmaceutical PreparationsPhosphorylation SitePhylogenetic AnalysisPolymersPropertyProtein BiochemistryProteinsProteomeReportingRespirationRoleSepsisSerineSolubilitySourceSpectroscopy, Fourier Transform InfraredStressStretchingStructureSurfaceTestingTimeToxic effectTranslatingTreatment ProtocolsVirulenceWaterYeastsaqueousbiological adaptation to stressdrug developmentfascinateforward geneticsfungusgain of functiongenome-wideimprovedin silicoin vivoin vivo evaluationinhibitorlink proteinmembermortalitymouse modelmutantnanoparticlenoveloropharyngeal thrushpathogenpharmacologicpreventprotein protein interactionpublic health relevancescreeningsuccesssurfactanttraitvaginal candidiasis
项目摘要
Abstract
Candida albicans causes half of all invasive fungal infections in humans. Its success as a pathogen is due to its
ability to adapt and thrive in various microenvironments in the host. Using a forward genetics screen, we identified
an uncharacterized gene NDU1 whose loss caused C. albicans to lose viability on alternative carbon sources
and made the organism completely avirulent in vivo. We found that Candida-Ndu1 protein possesses three
evolutionarily acquired stretches of amino acid inserts (~64 amino acids), absent from all other eukaryotes
including humans. We reported for the first time that ~17% of the Candida proteome possess “additional” sets
of evolutionarily acquired amino-acid inserts, that are absent from all non-CTG clade eukaryotes, including
humans. The role of insert regions in C. albicans proteome remains to be unraveled. We have shown that the
Ndu1 insertion sequences are vital and required for Ndu1’s activity. In aim 1, the mechanistic contribution of
Ndu1 inserts will be investigated by protein biochemistry studies. The role of insert regions in other Candida
proteins will also be evaluated , to understand if inserts are universally important for function.
Considering Ndu1 is important for growth and virulence in vivo, we targeted Ndu1 and its insert regions for
development of antifungal molecules. We identified a repurposed FDA approved drug niclosamide (NCL), and
developed Eudragit EPO nanoparticle formulations of this molecule to enhance its solubility and bioavailability.
NCL nanoparticles (NCL-EPO-NP) could prevent growth of Candida in alternative carbon sources, penetrate
and dismantle mature biofilms in vitro, and eradicate it in vivo in biofilm models of mucosal candidiasis. The
activity of NCL-NP was 6-10 fold higher than the generic drug alone. In Aim 2, we further characterize and
evaluate NCL-EPO-NP for their pharmacokinetics and oral biodistribution, toxicity profiles and in vivo efficacy in
an oral regimen for treatment of oral candidiasis, as standalone or adjunct therapy with other antifungal drugs.
摘要
白色念珠菌导致人类所有侵袭性真菌感染的一半。它作为病原体的成功是因为它
在宿主的各种微环境中适应和茁壮成长的能力。通过正向遗传学筛选,我们发现
NDU 1基因缺失导致C.白色念珠菌在替代碳源上失去生存能力
并使该生物体在体内完全无毒。我们发现,Adipda-Ndu 1蛋白具有三个
进化获得的氨基酸插入片段(~64个氨基酸),在所有其他真核生物中缺失
包括人类我们首次报道了~17%的念珠菌蛋白质组具有“额外”集合
的进化获得的氨基酸插入,这是不存在于所有非CTG分支真核生物,包括
人类插入区在C.白念珠菌蛋白质组仍有待进一步研究。我们已经证明,
Ndu 1插入序列对于Ndu 1的活性是至关重要和必需的。在目标1中,
ndu 1插入物将通过蛋白质生物化学研究进行研究。插入区在其他念珠菌中的作用
还将评估蛋白质,以了解插入物是否对功能普遍重要。
考虑到Ndu 1对体内生长和毒力的重要性,我们靶向Ndu 1及其插入区域,
抗真菌分子的发展。我们发现了一种重新利用的FDA批准的药物氯硝柳胺(NCL),
开发了该分子的Eudragit EPO纳米颗粒制剂,以提高其溶解度和生物利用度。
NCL纳米粒(NCL-EPO-NP)可以抑制念珠菌在替代碳源中的生长,
并在体外拆除成熟生物膜,并在粘膜念珠菌病的生物膜模型中在体内根除它。的
NCL-NP的活性比单独的仿制药高6-10倍。在目标2中,我们进一步表征和
评价NCL-EPO-NP的药代动力学和口服生物分布、毒性特征和体内功效,
一种治疗口腔念珠菌病的口服方案,作为独立治疗或与其他抗真菌药物联合治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PRIYA UPPULURI其他文献
PRIYA UPPULURI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PRIYA UPPULURI', 18)}}的其他基金
Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis
针对菌丝对侧向酵母生长的调节机制作为对抗念珠菌病的新治疗方法
- 批准号:
10447678 - 财政年份:2019
- 资助金额:
$ 20.19万 - 项目类别:
Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis
针对菌丝对侧向酵母生长的调节机制作为对抗念珠菌病的新治疗方法
- 批准号:
10215503 - 财政年份:2019
- 资助金额:
$ 20.19万 - 项目类别:
Targeting the regulatory mechanism of hyphae to lateral yeast growth as a novel therapeutic approach against candidiasis
针对菌丝对侧向酵母生长的调节机制作为对抗念珠菌病的新治疗方法
- 批准号:
9817046 - 财政年份:2019
- 资助金额:
$ 20.19万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 20.19万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 20.19万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 20.19万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 20.19万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 20.19万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 20.19万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 20.19万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 20.19万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 20.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 20.19万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




